A dy­nam­ic on­col­o­gy duo team up on an I/O start­up fo­cused on next-gen sol­id tu­mor fight­ers

4 years ago
Financing
Startups

As GSK is forced to slam the brakes, Pfiz­er cruis­es ahead with a ‘break­through’ on RSV

4 years ago
FDA+

Hori­zon cooks up new rare dis­ease aware­ness cam­paign with blind Mas­terChef Chris­tine Ha

4 years ago
Pharma
Marketing

FDA slaps hold on Finch's mi­cro­bio­me C. dif­fi­cile treat­ment, as biotech blames Covid-19 and old man­u­fac­tur­er

4 years ago
R&D
FDA+

Biden con­tin­ues his pledge for Medicare drug price ne­go­ti­a­tions in State of the Union speech

4 years ago
Pharma
Coronavirus

That bull­ish stance Karyopharm took on its sub­group can­cer study da­ta? The FDA was­n't im­pressed

4 years ago
FDA+

FDA quick­ly fol­lows a vol­un­tary pause for CAR-T 2.0 with a clin­i­cal hold to in­ves­ti­gate 2 pa­tient deaths

4 years ago
Cell/Gene Tx
FDA+

Flag­ship's lat­est boast? A start­up that will 'rev­o­lu­tion­ize treat­men­t' for 'nine­ty per­cent of hu­man ill­ness'

4 years ago
Startups

Sanofi en­lists Ada­gene and its 'mask­ing' tech to de­vel­op new I/O drugs, in a deal po­ten­tial­ly worth $2.5B

4 years ago
Deals

SEC jumps in­to the Fi­bro­Gen fi­as­co with a sub­poe­na, prob­ing car­dio da­ta ma­nip­u­la­tion

4 years ago
FDA+
Law

Bay­er rush­es sup­port to Ukraine staff, help­ing with cash and hous­ing as Rus­sians at­tack ma­jor cities

4 years ago
Bioregnum
Pharma

How Op­er­a­tion Warp Speed clashed with Pfiz­er in the ear­ly days of the pan­dem­ic

4 years ago
Pharma
Coronavirus

Im­prov­ing can­cer drug re­search: FDA re­works and fi­nal­izes guid­ance doc­u­ments

4 years ago
FDA+

No­vavax dou­bles down on promise to pro­duce 2B Nu­vax­ovid dos­es — this year

4 years ago
R&D
Pharma

Cure­Vac es­tab­lish­es RNA print­er-spe­cif­ic com­pa­ny as light at the end of tun­nel nears

4 years ago
Pharma
Manufacturing

Mar­ket­ingRx roundup: Rare dis­ease day ef­forts from Pfiz­er, Hori­zon and more; J&J re­boots on­line MG cam­paign

4 years ago
Pharma
Marketing

Pfiz­er joins Sanofi on the C. dif­fi­cile fail­ure train af­ter its vac­cine flopped a PhI­II study

4 years ago
R&D

Epizyme joins the queue of biotechs now hand­ing out pink slips, con­serv­ing cash

4 years ago
People
R&D

Mar­ket­ingRx Matchup: Is it No­vo Nordisk’s Ozem­pic or Lil­ly and BI’s Jar­diance for the win in Type 2 ads?

4 years ago
Pharma
Marketing

A new JAK in­hibitor earns FDA nod in myelofi­bro­sis, set­ting up a fight with In­cyte, Bris­tol My­ers

4 years ago
FDA+

FDA re­jects Gilead’s next big HIV drug over glass vial is­sues

4 years ago
FDA+

Bris­tol My­ers part­ner comes through on IL-12 ef­fort. Now it's Ru­pert Vessey's turn at bat

4 years ago
Deals
R&D

Ab­b­Vie adds to its neu­ro pipeline with a $1B buy­out deal, bolt­ing on a new drug aimed at Alzheimer’s

4 years ago
Deals

In the wake of pa­tient death, Sutro says its Chi­nese part­ner is re­think­ing their deal and with­hold­ing $40M

4 years ago
Deals
First page Previous page 574575576577578579580 Next page Last page
A service from the Financial Times